xl888
Small moleculeexperimental
Clinical trial activity
4 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2008 (NCT00796484)
Timeline
2000s
- Jan 1, 2008
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- HSP90INHIBITOR
HSP90 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- xl888
- xl888
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03095781 | Phase 1 | Sep 1, 2017 | Emory University, Exelixis, Merck |
| NCT02721459 | Phase 1 | Aug 1, 2016 | Exelixis, Genentech, University of South Florida |
| NCT01657591 | Phase 1 | Jul 27, 2012 | Exelixis, University of South Florida |
| NCT00796484 | Phase 1 | Nov 1, 2008 | Exelixis |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Exelixis | For profit | 4 | 1 | 1 | 2008 |
| University of South Florida | Academic/Hospital | 2 | 2 | 1 | 2012 |
| Emory University | Academic/Hospital | 1 | 1 | 1 | 2017 |
| Genentech | For profit | 1 | 0 | 1 | 2016 |
| Merck | For profit | 1 | 0 | 1 | 2017 |
5 organizations
Page 1 / 1